Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

DocMorris stock

DOCM.SW
CH0042615283
A0Q6J0

Price

29.54
Today +/-
+0.69
Today %
+2.19 %

DocMorris stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the DocMorris stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the DocMorris stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the DocMorris stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze DocMorris's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

DocMorris Stock Price History

DateDocMorris Price
11/22/202429.54 undefined
11/21/202428.90 undefined
11/20/202430.78 undefined
11/19/202430.80 undefined
11/18/202432.74 undefined
11/15/202433.58 undefined
11/14/202434.80 undefined
11/13/202436.48 undefined
11/12/202437.56 undefined
11/11/202438.98 undefined
11/8/202436.88 undefined
11/7/202433.98 undefined
11/6/202433.40 undefined
11/5/202433.42 undefined
11/4/202433.18 undefined
11/1/202434.58 undefined
10/31/202434.00 undefined
10/30/202435.26 undefined
10/29/202434.76 undefined
10/28/202433.82 undefined

DocMorris Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into DocMorris, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by DocMorris from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects DocMorris’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of DocMorris. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into DocMorris’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing DocMorris’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on DocMorris’s growth potential.

DocMorris Revenue, EBIT and net profit per share

DateDocMorris RevenueDocMorris EBITDocMorris Net Income
2029e3.12 B undefined0 undefined0 undefined
2028e2.83 B undefined128.85 M undefined124.52 M undefined
2027e2.52 B undefined95.54 M undefined92.98 M undefined
2026e1.63 B undefined-2.64 M undefined-16.9 M undefined
2025e1.32 B undefined-49.95 M undefined-71.04 M undefined
2024e1.06 B undefined-90.31 M undefined-102.41 M undefined
2023969.46 M undefined-81.81 M undefined82.28 M undefined
20221.61 B undefined-133.9 M undefined-171.1 M undefined
20211.73 B undefined-189.8 M undefined-225.7 M undefined
20201.48 B undefined-109.3 M undefined-135.7 M undefined
20191.36 B undefined-63.2 M undefined-52.4 M undefined
20181.21 B undefined-31.4 M undefined-39 M undefined
2017982.9 M undefined-32.2 M undefined-36.2 M undefined
2016879.5 M undefined-7 M undefined-12.8 M undefined
2015834.4 M undefined8.4 M undefined3.4 M undefined
2014915.6 M undefined8.2 M undefined7.2 M undefined
2013910.6 M undefined-3.2 M undefined-15.5 M undefined
2012523.3 M undefined2.6 M undefined6.1 M undefined

DocMorris Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0.520.910.920.830.880.981.211.361.481.731.610.971.061.321.632.522.833.12
-74.000.55-8.855.4011.7222.9112.268.9316.94-6.84-39.749.3924.1523.7154.5512.3610.29
14.3415.1615.1914.9915.0214.9715.8215.3516.8715.4115.2420.9519.1515.4312.478.077.186.51
75138139125132147191208249266245203000000
6-1573-12-36-39-52-135-225-17182-102-71-16921240
--350.00-146.67-57.14-500.00200.008.3333.33159.6266.67-24.00-147.95-224.39-30.39-77.46-675.0034.78-
3.23.23.43.43.75.56.38.79.19.610.811.67000000
------------------
Details

Keystats

ⓘ

Revenue and Growth

The DocMorris Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the DocMorris is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
201220132014201520162017201820192020202120222023
                       
55.231.621.525.525.4107.9230.8204.9301278.2156.4151.05
80.873.880.572.571.48492.3126.7114.9132129.455.39
6.573.75.88.612.111.51615.19.99.510.94
41.634.436.134.848.359.369.470.692.992.583.251.76
3.42.93.43.7610.212.79.915.324.517.424.54
187.5149.7145.2142.3159.7273.5416.7428.1539.2537.1395.9293.67
19.519.123.626.226.229.734.377.196.698.796.862.05
1.21.41.63.8421.37.27.56.33.61.61
2.10.60.50.71.800.9624.22526.511.14
38.839.239.343.352.7147.692.2130.6169.3177171.1134.71
11.711.21110.510.40172.4334.7435.3418.4400.8360.37
5.14.176.76.898.68.16.46.74.82.86
78.475.68391.2101.9188.3309.7563.7739.3732.1703.6572.75
0.270.230.230.230.260.460.730.991.281.271.10.87
                       
18.718.718.718.724.935.848.1262.2315.8335.8404.7411.02
26.124.624.622.70272.2000000
53.737.642.944.992.80416.5183.3284.5234.875.4157.48
-6.1-6.1-7.5-12.5-13-12.8-15.6-34.7-36.6-54.4-68.7-79.32
000000000000
92.474.878.773.8104.7295.2449410.8563.7516.2411.4489.17
71.664.365.173.571.784.585.893.893.3132.2112.838.47
9.513.514.212.213.9192527.943.553.751.837.29
148.64.22.652.55.14.63.513.110.215.66.69
000000000000
1.10.50.50.50.110.43.587.46.816.461.297.87
96.286.98488.8138.2119118.9212.6156.7212.5241.4180.32
77.258.157.862.39.132144.7350.2563.8552.7493.1247.05
1.81.91.61.61.53.55.56.28.37.66.96.95
4.44.97.38.18.91313.717.21811.47.31.58
83.464.966.77219.548.5163.9373.6590.1571.7507.3255.57
179.6151.8150.7160.8157.7167.5282.8586.2746.8784.2748.7435.89
0.270.230.230.230.260.460.7311.311.31.160.93
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of DocMorris provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand DocMorris's financial health and stability.

Assets

DocMorris's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that DocMorris must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of DocMorris after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into DocMorris's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201220132014201520162017201820192020202120222023
6-1573-12-36-39-52-135-225-171-117
161597917183139516244
000000000000
130-94-17-4-22-32-63-6-53
-15103719-2934401838
0222221412141516
000000020021
202718-13-22-33-82-67-130-97-87
-5-10-15-15-19-21-31-41-59-63-59-27
-13-11-15-16-23-62-140-143-199-67-89219
-800-1-3-40-108-101-140-3-30247
000000000000
-7-1704-3-56112200157-70-202
49400422221840206187420
40-14-123716529720036317939-202
-----------3.00-
-1-10-1-10000000
47-23-103082122-2695-22-151-72
15.81-8.64-8.593.64-33.76-43.87-64.73-124.08-127.34-194.11-156.58-115.12
000000000000

DocMorris stock margins

The DocMorris margin analysis displays the gross margin, EBIT margin, as well as the profit margin of DocMorris. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for DocMorris.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the DocMorris's sales revenue. A higher gross margin percentage indicates that the DocMorris retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the DocMorris's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the DocMorris's total revenue generated. When comparing the revenue margin year over year, investors can gauge the DocMorris's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the DocMorris. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the DocMorris's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

DocMorris Margin History

DocMorris Gross marginDocMorris Profit marginDocMorris EBIT marginDocMorris Profit margin
2029e20.98 %0 %0 %
2028e20.98 %4.56 %4.4 %
2027e20.98 %3.8 %3.7 %
2026e20.98 %-0.16 %-1.04 %
2025e20.98 %-3.8 %-5.4 %
2024e20.98 %-8.52 %-9.66 %
202320.98 %-8.44 %8.49 %
202215.27 %-8.33 %-10.64 %
202115.41 %-10.99 %-13.07 %
202016.86 %-7.4 %-9.19 %
201915.4 %-4.66 %-3.87 %
201815.86 %-2.6 %-3.23 %
201715.03 %-3.28 %-3.68 %
201615.02 %-0.8 %-1.46 %
201515.06 %1.01 %0.41 %
201415.26 %0.9 %0.79 %
201315.21 %-0.35 %-1.7 %
201214.37 %0.5 %1.17 %

DocMorris Stock Sales Revenue, EBIT, Earnings per Share

The DocMorris earnings per share therefore indicates how much revenue DocMorris has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue DocMorris earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates DocMorris's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of DocMorris’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating DocMorris's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

DocMorris Revenue, EBIT and net profit per share

DateDocMorris Sales per ShareDocMorris EBIT per shareDocMorris Earnings per Share
2029e241.76 undefined0 undefined0 undefined
2028e219.2 undefined0 undefined9.66 undefined
2027e195.09 undefined0 undefined7.21 undefined
2026e126.31 undefined0 undefined-1.31 undefined
2025e102.04 undefined0 undefined-5.51 undefined
2024e82.19 undefined0 undefined-7.94 undefined
202383.05 undefined-7.01 undefined7.05 undefined
2022148.91 undefined-12.4 undefined-15.84 undefined
2021179.84 undefined-19.77 undefined-23.51 undefined
2020162.3 undefined-12.01 undefined-14.91 undefined
2019155.8 undefined-7.26 undefined-6.02 undefined
2018191.6 undefined-4.98 undefined-6.19 undefined
2017178.71 undefined-5.85 undefined-6.58 undefined
2016237.7 undefined-1.89 undefined-3.46 undefined
2015245.41 undefined2.47 undefined1 undefined
2014269.29 undefined2.41 undefined2.12 undefined
2013284.56 undefined-1 undefined-4.84 undefined
2012163.53 undefined0.81 undefined1.91 undefined

DocMorris business model

The Zur Rose Group AG is a Swiss company that specializes in online trading of medications and health products. The company was founded in 1993 in Steckborn and initially focused on the mail order of homeopathic medicines. In 1997, the online shop www.zurrose.de was opened and the company began to expand its distribution to non-homeopathic medicines. The business model of the Zur Rose Group AG is based on a three-pillar model, encompassing e-commerce, wholesale, and healthcare. In the e-commerce sector, the company operates online pharmacies in various countries including Germany, France, Austria, the Netherlands, and Switzerland. In the wholesale sector, the company supplies pharmacies and hospitals with medicines and medical products. In the healthcare sector, the company offers various services in healthcare, from the production of medicines to the processing of prescriptions. The Zur Rose Group AG offers a wide range of products and services including prescription and over-the-counter medications, natural remedies, cosmetic products, dietary supplements, and medical devices. The company aims to provide its customers with a comprehensive selection of high-quality products and works closely with its suppliers to ensure that all products meet the highest quality standards. In the e-commerce sector, the company operates various online pharmacies, including Zur Rose Apotheke in Germany, Zur Rose Apotheke in Austria, and Doctipharma in France. These online pharmacies offer a wide range of medications and health products that can be ordered online and conveniently delivered to customers' homes. The online pharmacies are open 24/7, allowing customers to quickly and easily order their needed medications. In the wholesale sector, the company offers a wide range of pharmaceutical products and medical devices to pharmacies and hospitals. The company works closely with its suppliers to ensure that all products meet the highest quality standards. Additionally, the company also provides a fast and reliable delivery service to ensure that its customers are always provided with the needed medications and medical products. In the healthcare sector, the company offers various services in healthcare, including digitalization solutions for pharmacies, manufacturing of medications, and processing of prescriptions. The company works closely with its customers to offer tailored solutions that meet their individual requirements. Over the years, the Zur Rose Group AG has become a leading provider in the online trading of medications and health products. The company has distinguished itself through its wide product range, fast and reliable delivery service, and excellent customer service. Additionally, the company has also invested in the development of new technologies to ensure that it can always offer its customers the best products and services. Overall, the Zur Rose Group AG is an innovative company built on a long history in healthcare. The company strives to offer its customers a wide range of high-quality products and services and has established itself as a leading provider in the online trading of medications and health products. DocMorris is one of the most popular companies on Eulerpool.com.

DocMorris SWOT Analysis

Strengths

Zur Rose Group AG has a strong brand presence and recognition in the pharmaceutical industry.

The company has a wide range of products and services, providing convenience and accessibility to customers.

Zur Rose Group AG benefits from economies of scale due to its large customer base and extensive distribution network.

Weaknesses

Zur Rose Group AG faces intense competition from both traditional brick-and-mortar pharmacies and other online pharmacies.

The company's profitability is dependent on reimbursement rates from healthcare insurance providers.

Zur Rose Group AG may also face challenges in gaining customer trust and loyalty due to the sensitive nature of the pharmaceutical industry.

Opportunities

The growing trend towards e-commerce and digitalization in the healthcare sector provides an opportunity for Zur Rose Group AG to expand its online presence.

The increasing demand for personalized healthcare services opens avenues for the company to offer tailored product recommendations and improved customer experience.

Zur Rose Group AG can explore partnerships and collaborations with healthcare providers and insurers to enhance its service offerings.

Threats

Regulatory changes and compliance requirements pose a significant threat to Zur Rose Group AG's operations and profitability.

The emergence of counterfeit drugs in the online market can tarnish the company's reputation and erode customer trust.

Changes in consumer behavior and preferences can impact the demand for online pharmaceutical services.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

DocMorris Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

DocMorris historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

DocMorris shares outstanding

The number of shares was DocMorris in 2023 — This indicates how many shares 11.674 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue DocMorris earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates DocMorris's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of DocMorris’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating DocMorris's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for DocMorris.

Eulerpool ESG Scorecard© for the DocMorris stock

Eulerpool World ESG Rating (EESG©)

61/ 100

🌱 Environment

50

👫 Social

45

🏛️ Governance

89

Environment

Scope 1 - Direct Emissions
260
Scope 2 - Indirect emissions from purchased energy
2,692
Scope 3 - Indirect emissions within the value chain
4,748
Total CO₂ emissions
2,952
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees54
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

DocMorris shareholders

%
Name
Stocks
Change
Date
22.39405 % UBS Asset Management (Switzerland)2,888,142-12,10910/22/2024
5.51247 % Sands Capital Management, LLC710,938103,7255/27/2024
3.58262 % BNP Paribas SA462,047462,0474/18/2024
3.43626 % PSquared Asset Management AG443,17116,2008/20/2024
3.30940 % Z¿rcher Kantonalbank (Asset Management)426,810262,9116/21/2024
3.03479 % BlackRock Institutional Trust Company, N.A.391,394012/31/2023
2.94644 % Shareholder Value Management AG380,00003/31/2024
2.62644 % The Vanguard Group, Inc.338,73073,7779/30/2024
0.89519 % Oberhaensli (Walter)115,4522,58212/31/2023
0.87843 % Premier Asset Management Ltd113,291-6,8437/31/2024
1
2
3
4
5
...
10

DocMorris Executives and Management Board

Mr. Walter Hess

(58)
DocMorris Chief Executive Officer, Member of the Executive Board
Compensation 1.45 M

Prof. Stefan Feuerstein

(68)
DocMorris Non-Executive Independent Vice Chairman of the Board of Directors
Compensation 302,000

Mr. Walter Oberhaensli

(65)
DocMorris Non-Executive Chairman of the Board (since 1996)
Compensation 283,000

Prof. Dr. Andrea Belliger

(53)
DocMorris Non-Executive Independent Member of the Board of Directors
Compensation 180,000

Dr. Christian Mielsch

(60)
DocMorris Non-Executive Independent Member of the Board of Directors
Compensation 151,000
1
2
3

Most common questions regarding DocMorris

What values and corporate philosophy does DocMorris represent?

Zur Rose Group AG is a leading online pharmacy and healthcare provider. With a strong focus on customer satisfaction and quality, the company aims to improve the health and well-being of its customers. Its corporate philosophy revolves around innovation, efficiency, and sustainability. By utilizing advanced technology and digital solutions, Zur Rose Group AG ensures seamless and convenient access to a wide range of pharmaceutical products and healthcare services. The company places great value on trust, reliability, and transparency, aiming to establish long-lasting relationships with its customers. Zur Rose Group AG's commitment to providing accessible and affordable healthcare sets it apart in the industry.

In which countries and regions is DocMorris primarily present?

Zur Rose Group AG is primarily present in countries and regions including Switzerland, Germany, and Austria.

What significant milestones has the company DocMorris achieved?

Zur Rose Group AG, a leading online pharmacy in Europe, has achieved several significant milestones. The company went public in 2017, making it the first publicly traded online pharmacy in Switzerland. In 2018, Zur Rose Group AG acquired the pharmacy business of medpex, Germany's second-largest online pharmacy. This strategic move strengthened its position in Europe's largest pharmaceutical market. In 2020, the company successfully completed the acquisition of Apotal, another prominent online pharmacy in Germany. These milestones demonstrate Zur Rose Group AG's commitment to expanding its market presence, enhancing customer access to high-quality healthcare products, and solidifying its position as a trusted online pharmacy leader.

What is the history and background of the company DocMorris?

The Zur Rose Group AG is a renowned Swiss company specializing in healthcare and pharmacy services. Founded in 1993 by Walter Oberhänsli, it started as a local pharmacy in Zurich. Over the years, Zur Rose Group AG expanded its operations and established itself as a prominent e-commerce platform for pharmaceuticals, providing customers with easy access to a wide range of healthcare products. The company has since grown into one of Europe's leading online pharmacies, serving millions of customers across multiple countries. With its commitment to innovation and customer-centric approach, Zur Rose Group AG continues to revolutionize the healthcare industry by combining digital solutions with traditional pharmaceutical services.

Who are the main competitors of DocMorris in the market?

The main competitors of Zur Rose Group AG in the market include established online pharmacy platforms such as Shop Apotheke and DocMorris, as well as traditional brick-and-mortar pharmacies. Zur Rose Group AG competes with these companies by offering a convenient and user-friendly online platform for customers to order prescription and over-the-counter medications. With its strong emphasis on customer service and a wide range of products, Zur Rose Group AG aims to stay competitive in the rapidly growing online pharmacy market.

In which industries is DocMorris primarily active?

Zur Rose Group AG is primarily active in the healthcare and pharmaceutical industries.

What is the business model of DocMorris?

The business model of Zur Rose Group AG is focused on providing pharmaceutical and healthcare services. As a leading online pharmacy in Europe, Zur Rose offers a wide range of products and services. The company operates in two segments, namely the Pharmacy and the Services segments. Through its online platform, Zur Rose enables customers to order prescription and over-the-counter drugs, as well as healthcare products, from the comfort of their homes. Additionally, Zur Rose provides services to healthcare professionals, such as logistics and wholesale services. Overall, Zur Rose's business model aims to enhance the accessibility and convenience of pharmaceutical and healthcare products for its customers.

What is the P/E ratio of DocMorris 2024?

The DocMorris P/E ratio is -3.37.

What is the P/S ratio of DocMorris 2024?

The DocMorris P/S ratio is 0.33.

What is the Quality Investing of DocMorris?

The Quality Investing for DocMorris is 3/10.

What is the revenue of DocMorris 2024?

The expected DocMorris revenue is 1.06 B CHF.

How high is the profit of DocMorris 2024?

The expected DocMorris profit is -102.41 M CHF.

What is the business model of DocMorris

The Zur Rose Group AG is a leading company in the healthcare sector and offers a wide range of products and services, ranging from pharmaceuticals to care products to medical advice and healthcare services. The company is headquartered in Switzerland and operates in several European countries, including Germany, Austria, France, Spain, and Italy. The core business of the Zur Rose Group AG is the online sale of prescription and over-the-counter medications. Customers can order their medications through the Zur Rose Group AG platform and have them delivered to their homes free of charge. In order to provide this service, the Zur Rose Group AG has built its own mail-order pharmacy that complies with all legal requirements and where all medications are checked by qualified pharmacists. In addition to the mail-order pharmacy, the Zur Rose Group AG also operates a number of local pharmacies, known as "DocMorris." These pharmacies also offer prescription and over-the-counter medications, as well as care products and advice from qualified pharmacists. The Zur Rose Group AG has set itself the goal of becoming the leading pharmacy brand in Europe and is therefore continuously expanding into new markets. Another important business area of the Zur Rose Group AG is healthcare services. Here, the company offers services such as medical advice over the phone, email, or live chat. The Zur Rose Group AG also operates its own health centers, where patients can receive medical advice and treatment, as well as various health checks and preventive examinations. In order to further expand its business, the Zur Rose Group AG has also invested in other areas in recent years. For example, the company has developed the platform "smartpatient," which supports patients in managing their health data and informing themselves about their illnesses and treatment options. In addition, the Zur Rose Group AG has a stake in the company Medpex, an online shop for pharmaceuticals and care products. Overall, the Zur Rose Group AG pursues a broad-based business model based on various pillars. The company benefits from the growing trend towards online commerce and digital healthcare. At the same time, the Zur Rose Group AG also relies on proven concepts such as local pharmacies to ensure comprehensive access to medications and healthcare services. In the future, the Zur Rose Group AG is likely to continue to grow strongly and further expand its position as one of the leading providers in the healthcare sector.

What is the DocMorris dividend?

DocMorris pays a dividend of 0 CHF distributed over payouts per year.

How often does DocMorris pay dividends?

The dividend cannot currently be calculated for DocMorris or the company does not pay out a dividend.

What is the DocMorris ISIN?

The ISIN of DocMorris is CH0042615283.

What is the DocMorris WKN?

The WKN of DocMorris is A0Q6J0.

What is the DocMorris ticker?

The ticker of DocMorris is DOCM.SW.

How much dividend does DocMorris pay?

Over the past 12 months, DocMorris paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, DocMorris is expected to pay a dividend of 0 CHF.

What is the dividend yield of DocMorris?

The current dividend yield of DocMorris is .

When does DocMorris pay dividends?

DocMorris pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of DocMorris?

DocMorris paid dividends every year for the past 0 years.

What is the dividend of DocMorris?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is DocMorris located?

DocMorris is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von DocMorris kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of DocMorris from 11/25/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 11/25/2024.

When did DocMorris pay the last dividend?

The last dividend was paid out on 11/25/2024.

What was the dividend of DocMorris in the year 2023?

In the year 2023, DocMorris distributed 0 CHF as dividends.

In which currency does DocMorris pay out the dividend?

The dividends of DocMorris are distributed in CHF.

All fundamentals about DocMorris

Our stock analysis for DocMorris Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DocMorris Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.